

Heart valve disease Committee meeting 1

Date: 05/06/2019

Location: NGC Boardroom, Royal College of Physicians, London

Minutes: Final

Committee members present:	
Joy Ellery (JE)	(Present for notes 1 – 4)
Madalina Garbi (MG)	(Present for notes 1 – 4)
Marjan Jahangiri (MJ)	(Present for notes 1 – 4)
Rajesh Kharbanda (RKK)	(Present for notes 1 – 4)
Saul Myerson (SM)	(Present for notes 1 – 4)
Suzannah Power (SP)	(Present for notes 1 – 4)
Phil Smith (PS)	(Present for notes 1 – 4)

In attendance:		
Katie Broomfield (KB)	Project Manager, NGC	(Present for notes 1 – 4)
Jill Cobb (JC)	Information Specialist, NGC	(Present for notes 1 – 4)
Nicole Downes (ND)	Systematic Reviewer, NGC	(Present for notes 1 – 4)
Robert King (RK)	Health Economist, NGC	(Present for notes 1 – 4)
Catherine McEvoy (CME)	Guideline Commissioning Manager, NICE	(Present for notes 1 – 4)
Eleanor Samarasekera (ES)	Senior Research Fellow, NGC	(Present for notes 1 – 4)
Sharon Swain (SS)	Guideline Lead, NGC	(Present for notes 1 – 4)
Claire Townsend (CT)	Information Specialist, NGC	(Present for notes 1 – 4)
Janine Wigmore (JW)	Patient Involvement Programme Lead, NICE	(Present for notes 1 – 3.3)
George Wood (GW)	Systematic Reviewer, NGC	(Present for notes 1 – 4)

Apologies:	
Norman Briffa (NB)	Guideline Committee
Denise Parkin (DP)	Guideline Committee

1. Welcome and objectives for the meeting

PS welcomed the Committee members and attendees to the first meeting of the Heart Valve Disease guideline. The Committee members and attendees introduced themselves.

PS informed the Committee that apologies had been received. These are noted above.

PS outlined the objectives of the meeting.

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The DOI register was made available to PS. PS reviewed the DOI register and deemed that no committee members had DOIs that were in conflict with the agenda topics under discussion at this meeting. All members were asked to verbally declare all declarations of interest made to date.

PS also asked everyone to verbally declare any interests that have arisen since application. The following interests were received for this committee meeting:

Committee Declarations of Interest

N.B. The Committee members were recruited to this guideline using NICE DOI policy published April 2018.

Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
NB	President of the British Heart Valve Society	Direct non-financial	Specific No action other than the process of open declaration
	Position paper on research in heart valve disease and postoperative echocardiography: <ul style="list-style-type: none">- Indications for echocardiography of replacement heart valves: a joint statement from British Heart valve Society and British Society of Echocardiography	Direct non-financial	Specific Partial exclusion Withdraw from recommendations on the review of monitoring

Joy Ellery	I am a Lay Member of Southwark Clinical Commissioning Group and we commission services for our residents from acute and community health services.	Direct non-financial	Non-specific No action other than the process of open declaration
Madalina Garbi	Honorary Secretary of the British Heart Valve Society. Stepped down upon appointment to this guideline committee.	Direct non-financial	Specific No action other than the process of open declaration
	Secretary and Treasurer of the ESC Council on Valvular Heart Disease. Stepped down upon appointment to this guideline committee.	Direct non-financial	Specific No action other than the process of open declaration
	Publication: “Exercise Stress Echocardiography in Degenerative Mitral Regurgitation. Back to the Origins”. <i>Lancellotti P, Garbi M. (Circulation-Imaging, September 2018)</i>	Direct non-financial	Specific No action other than the process of open declaration
	Publication: “2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.” <i>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al, ESC Scientific Document Group. Collaborators Deaton C ... Garbi M ... Nelson-Piercy C. (EHJ, Sep 2018)</i>	Direct non-financial	Specific No action other than the process of open declaration
	Publication: “Progression of secondary mitral regurgitation: from heart failure to valvular heart failure”. <i>Lancellotti P, Garbi M. (EHJ-CVI, March 2018)</i>	Direct non-financial	Non-specific No action other than the process of open declaration
Publication: “Stress echocardiography in patients with native valvular heart disease”. <i>Lancellotti P, ..., Garbi M. (Heart, Dec</i>	Direct non-financial	Specific Partial exclusion Withdraw from discussions of the	

	<p>2017)</p> <p><i>Publication:</i></p> <p>“Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging”. <i>Galderisi M, ..., Garbi M, et al. (EHJ-CVI, Dec 2017)</i></p> <p><i>Publication:</i></p> <p>“The need for appropriate use criteria: the proof of the pudding”. <i>Lancellotti P, Garbi M. (EHJ-CVI, Nov 2017)</i></p> <p>Position paper on research in heart valve disease and postoperative echocardiography: Indications for echocardiography of replacement heart valves: a joint statement from British Heart valve Society and British Society of Echocardiography</p>	<p>Direct non-financial</p> <p>Direct non-financial</p> <p>Direct non-financial</p>	<p>recommendations if paper included in the evidence review</p> <p>Non-specific No action other than the process of open declaration</p> <p>Non-specific No action other than the process of open declaration</p> <p>Specific Partial exclusion Withdraw from recommendations on the review of monitoring</p>
<p>Marjan Jahangiri</p>	<p>I am the co-chair of Adult Cardiac Surgery Sub-committee of The Society for Cardiothoracic Surgery of GB & Ireland.</p> <p>I have agreed to limit my already very limited private practice to only the care of patients with non-valvular heart disease. My private practice comprises approximately 2% of my practice and I agree to limit this. I will not see patients with suspected or diagnosed heart valve disease.</p>	<p>Direct non-financial</p> <p>Direct financial</p>	<p>Specific No action other than the process of open declaration</p> <p>Non-specific No action other than the process of open declaration</p>

	BHF grant in 2007. The project was to look at the role of anticoagulation/anti-platelet therapy following tissue aortic valve replacement. The project finished in 2008 and the research fellow was awarded his MDRes.	Indirect financial	Specific No action other than the process of open declaration
Rajesh Kharbanda	I will cease private work related to valve disease for the duration guideline development. I will cease paid teaching for the duration of the guideline development Sponsorship to attend as speaker at a medical conference covering registration, travel and accommodation. (Transcatheter Valve Therapy meeting, Chicago)	Direct financial Direct financial Direct financial	Specific No action other than the process of open declaration Specific No action other than the process of open declaration Specific No action other than the process of open declaration
Saul Myerson	Previous and current research focusses significantly on valve disease. My areas of research cover less than 50% of the scope of the planned guidance, and within these areas, the research is focussed on specific aspects rather than the whole area, e.g. mainly cardiac MRI for assessment rather than other imaging modalities; and the use of ACE inhibitor medication for aortic stenosis, but not other valve lesions. I have a small private cardiology practice, which includes some patients with valve disease. I have however agreed not to see private patients with a major diagnosis of valve disease, for the duration of	Indirect financial Direct financial	Specific No action other than the process of open declaration. See actions below for individual publications. Specific No action other than the process of open declaration

	<p>my time on the guideline committee.</p> <p>Publication: Myocardial Scar and Mortality in Severe Aortic Stenosis: Data from the BSCMR Valve Consortium. Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, Dobson LE, Pica S, Loudon M, Malley T, Rigolli M, Foley JRJ, Bijsterveld P, Law GR, Dweck MR, Myerson SG, McCann GP, Prasad SK, Moon JC, Greenwood JP. Circulation 2018 (in press)</p> <p>Cardiac auscultation poorly predicts valvular heart disease in asymptomatic patients Gardezi SK, Myerson SG, Chambers J, Coffey S, d’Arcy J, Hobbs FDR, Holt J, Kennedy A, Loudon M, Prendergast A, Prothero A, Wilson J, Prendergast BD. Heart 2018; 104(22): 1832-5 (doi.org/10.1136/heartjnl-2018-313082)</p> <p>Appropriateness criteria for the use of cardiovascular imaging in native heart valve disease: a European Association of Cardiovascular Imaging report of literature review and current practice Chambers J, Garbi M, Nieman K, Myerson S, Pierard LA, Habib G, Zamorano JL, Edvardsen T, Lancellotti P. Eur J Cardiovasc Imag 2017; 18: 489-98</p> <p>Large-Scale Unselected Community Echocardiographic Screening Reveals a Major Burden of Undiagnosed Valvular Heart Disease in Older People d’Arcy JL, Coffey S, Loudon MA,</p>	<p>Direct non-financial</p> <p>Direct non-financial</p> <p>Direct non-financial</p> <p>Direct non-financial</p>	<p>Non-specific No action other than the process of open declaration.</p> <p>Specific Partial exclusion Withdraw from recommendations on review of diagnosis of heart valve disease</p> <p>Non-specific No action other than the process of open declaration.</p> <p>Non-specific No action other than the process of open declaration.</p>
--	---	---	---

	<p>Kennedy A, Pearson-Stuttard J, Birks J, Frangou E, Farmer AJ, Mant D, Wilson J, Myerson SG, Prendergast BP Eur Heart J 2016 Dec 14; 37: 3515-22; doi:10.1093/eurheartj/ehw229</p> <p>Determination of clinical outcome in mitral regurgitation with cardiovascular magnetic resonance quantitation Myerson SG, d’Arcy J, Christiansen JP, Dobson LE, Mohiaddin R, Francis JM, Prendergast B, Greenwood J, Karamitsos TD, Neubauer S Circulation 2016;133: 2287-96</p> <p>Multimodality imaging in heart valve disease Chambers JB, Myerson S, Rajani R, Morgan-Hughes G, Dweck M OpenHeart 2016; Mar 8;3(1), doi: 10.1136/openhrt-2015-000330</p> <p>A prospective, double-blind, randomised controlled trial of the angiotensin converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, Prendergast B, Banning AP, Neubauer S, Myerson SG. EHJ- Cardiovascular Imaging 2015; 16: 834-841; doi: 10.1093/ehjci/jev043</p> <p>Aortic regurgitation quantification with cardiovascular magnetic resonance: association with clinical outcome. Myerson SG, D’Arcy J, Greenwood P, Mohiaddin R, Karamitsos TD, Francis JM, Banning AP, Christiansen, JP, Neubauer S. Circulation 2012; 126: 1452-60</p>	<p>Direct non-financial</p> <p>Direct non-financial</p> <p>Direct non-financial</p> <p>Direct non-financial</p> <p>Direct non-financial</p>	<p>Specific Partial exclusion Withdraw from recommendations on diagnosis of heart valve disease</p> <p>Specific Partial exclusion Withdraw from recommendations on diagnosis of heart valve disease</p> <p>Specific Partial exclusion Withdraw from recommendations on diagnosis of heart valve disease</p> <p>Specific Partial exclusion Withdraw from recommendations on diagnosis of heart valve disease</p> <p>Specific</p>
--	--	---	---

	Heart valve disease : investigation by cardiovascular magnetic resonance Myerson SG, J Cardiovasc Magn Reson Imaging. 2012; 14: 7-30	Direct non-financial	Partial exclusion Withdraw from recommendations on diagnosis of heart valve disease
Denise Parkin	None to date	-	-
Suzannah Power	Lay Member, BaNES CCG Co-Applicant, CBT/AF research, University of Birmingham Institute of Cardiovascular Sciences Lay Member, Health Literacy Collaborative (NHSE)	Direct non-financial Indirect financial Direct non-financial	Non-specific No action other than the process of open declaration Non-specific No action other than the process of open declaration Non-specific No action other than the process of open declaration
Phil Smith	I am Co-Editor in Chief of Practical Neurology, and receive an annual honorarium from the BMJ for this. I do not hold any position relevant to the guideline.	Direct financial	Non-specific No action other than the process of open declaration
Vassilios Vassiliou	Editorial Board: Oxford Medical Case Reports, Oxford University Press (honorarium received in 2017 and 2018). Editorial Board: European Journal of Preventive Cardiology, SAGE Editorial Board: World Journal of Cardiology, Baishiden Lecturer, Event supported by Pfizer: GP educational event on	Direct financial Direct non-financial Direct non-financial Direct financial	Specific No action other than the process of open declaration Specific No action other than the process of open declaration Specific No action other than the process of open declaration Non-specific No action other

	Atrial Fibrillation. Received lecturer honorarium.		than the process of open declaration
	Lecturer, Event supported by Daichii-Sankyo: ESC Update on Cardiology for medical trainees. Received lecturer honorarium.	Direct financial	Specific No action other than the process of open declaration
	Research through the Royal Brompton Hospital and Imperial College, Norfolk and Norwich university Hospital and University of East Anglia and the BSCMR consortium; leading to publications relating to valve disease.	Indirect financial	Specific No action other than the process of open declaration. Actions for individual publications details below.
	PMID 30002099: Myocardial Scar and Mortality in Severe Aortic Stenosis	Direct non-financial	Non-specific No action other than the process of open declaration
	PMID 30266917: Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis	Direct non-financial	Non-specific No action other than the process of open declaration
	PMID 29914867: Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis: A Multicenter Cardiac Magnetic Resonance Study	Direct non-financial	Specific No action other than the process of open declaration Specific
	PMID 29804897: Left Atrial Function Is Associated with Earlier Need for Cardiac Surgery in Moderate to Severe Mitral Regurgitation: Usefulness in Targeting for Early Surgery	Direct non-financial	Partial exclusion Withdraw from recommendations on indications for interventions
	PMID 28704465: Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance	Direct non-financial	Non-specific No action other than the process of open declaration
	PMID 28359524: Midwall Fibrosis	Direct non-	Non-specific

	and 5-Year Outcome in Moderate and Severe Aortic Stenosis	financial	No action other than the process of open declaration
	PMID 26588986: Clinical value of cardiovascular magnetic resonance in patients with MR-conditional pacemakers	Direct non-financial	Non-specific No action other than the process of open declaration
	PMID 24866867: Markers of left ventricular decompensation in aortic stenosis	Direct non-financial	Non-specific No action other than the process of open declaration
	PMID 25170097: Left ventricular hypertrophy with strain and aortic stenosis	Direct non-financial	Non-specific No action other than the process of open declaration

NICE DOI policy classifications are:

- Direct financial specific
- Direct financial non-specific
- Direct non-financial specific
- Direct non-financial non-specific
- Indirect financial specific
- Indirect financial non-specific

3. Presentations and discussion

3.1 SS gave a presentation on the NGC and declarations of interest.

3.2 CME gave a presentation on the role of the Guideline Commissioning Manager and working with NICE.

3.3 JW gave a presentation on the patient involvement programme at NICE.

3.4 JC gave a presentation on searching the evidence.

3.5 ES gave a presentation on reviewing the evidence.

3.6 RK gave a presentation on health economics.

3.7 MG gave a presentation on the scope and review questions.

3.8 ES led a discussion on the draft protocol for medical management.

3.9 GW led a discussion on the draft protocol for anticoagulant and antiplatelet therapy for biological valves.

4. Any other business

The group discussed next steps and agreed action points.

Date of next meeting: 16/07/2019

Location of next meeting: Royal College of Physicians, London